This is a material pipeline de-risking event for INMB. The statistically significant biomarker results across the full study population, strengthening in the target-enriched subgroup, directly validate the Phase 2b/3 registrational design. Watch for AAIC 2026 presentation (July 12-15) for complete dataset including dose-response and longitudinal trajectory. The favorable safety profile (no ARIA-E/H) is a key differentiator vs amyloid-clearing competitors. Monitor for any capital raise announcements to fund the registrational program.
Price Chart
Executive Summary
INmune Bio reported statistically significant treatment effects on a white matter MRI biomarker (chi-separation) from the Phase 2 MINDFuL trial of XPro1595 in early Alzheimer's disease. The full mITT population (n=200) showed p=0.0028 with a medium effect size (d=0.46), strengthening to d=0.59 in biomarker-enriched patients (n=100). These results validate target engagement and support the upcoming Phase 2b/3 registrational program, which has FDA Fast Track designation and End-of-Phase 2 alignment.
Key Facts
- Statistically significant treatment effect on myelin in full mITT population (p=0.0028; Cohen's d=0.46; n=200)
- Effect strengthened in biomarker-enriched patients (p=0.0098; d=0.59; n=100), validating precision-medicine approach
- FDA Fast Track designation granted May 14, 2026 for XPro in early Alzheimer's disease
- End-of-Phase 2 alignment secured with FDA on Phase 2b/3 seamless adaptive registrational design
- No ARIA-E or ARIA-H observed in Phase 2 MINDFuL trial — favorable safety differentiation vs amyloid-clearing agents
- Complete chi-separation dataset to be presented at AAIC 2026 (July 12-15, 2026 in London)
Financial Impact
No financial figures reported. Positive clinical catalyst for a $37M market cap biotech with no approved products — potential for significant stock re-rating on registrational program de-risking.
Risk Factors
- Phase 2b/3 registrational trial may fail to replicate these biomarker results on cognitive endpoints
- Company will require substantial additional funding to complete the registrational program — dilutive financing risk
- XPro1595 is not yet approved by FDA or any regulatory body; regulatory approval is uncertain
- Competition from approved amyloid-clearing therapies and other neuroinflammation-targeting programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-064144 |
| Document: ea0293325-8k_inmune.htm | 0001213900-26-064144 |
| Document: 0001213900-26-064144-index-headers.html | 0001213900-26-064144 |
| Document: 0001213900-26-064144-index.html | 0001213900-26-064144 |
| Document: 0001213900-26-064144.txt | 0001213900-26-064144 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 8-K | $1.61 | awaiting T+60 | — | $1.43 (−11.18%) |
Sep 16, 2026 5w ago | 3 | $2.18 | awaiting T+60 | — | $1.43 (−34.40%) |
Jul 9, 2026 15w ago | Press Release | $1.79 $1.93 | ▲ +7.82% | ▲ +6.19% | $1.43 (−20.11%) |
Jul 1, 2026 16w ago | 8-K | $1.68 | awaiting T+60 | — | $1.43 (+14.88%) |
Jun 23, 2026 17w ago | 8-K | $1.35 | awaiting T+60 | — | $1.43 (+5.93%) |
Jun 17, 2026 18w ago | 8-K | $1.45 | awaiting T+60 | — | $1.43 (−1.38%) |
Jun 2, 2026 20w ago | 8-K | $1.32 $2.40 | ▲ +81.82% | ▲ +79.32% | $1.43 (+8.33%) |
May 7, 2026 24w ago | Press Release | $1.43 $1.91 | ▲ +33.57% | ▲ +28.73% | $1.43 (−0.00%) |
May 5, 2026 24w ago | 8-K | $1.52 $1.75 | ▲ +15.13% | ▲ +13.07% | $1.43 (−5.92%) |
Apr 30, 2026 25w ago | Press Release | $1.43 | awaiting T+60 | — | $1.43 (−0.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers